Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control

BACKGROUND: Immune checkpoint inhibitors (CPIs) have revolutionized oncologic therapy but can lead to immune‐related adverse events (irAEs). Corticosteroids are first‐line treatment with escalation to biologic immunosuppression in refractory cases. CPI‐related gastroenterocolitis (GEC) affects 20%‐5...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Med
Päätekijät: Hughes, Michael S., Zheng, Hui, Zubiri, Leyre, Molina, Gabriel E., Chen, Steven T., Mooradian, Meghan J., Allen, Ian M., Reynolds, Kerry L., Dougan, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Clinical Cancer Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6718531/
https://ncbi.nlm.nih.gov/pubmed/31286682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2397
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia